# PhotoSonix Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/photosonix-medical

- Industry: Medical Devices & Equipment
- Headquarters: Ambler, US
- Website: www.photosonixmed.com
- Total disclosed funding: $1.5M
- Latest round: Seed (Jan 26, 2016)
- Investors on record: 2

## About

PhotoSonix Medical, Inc. is focused on delivering innovative solutions for acne treatment through their investigational device, CLENS™, which promotes a non-drug approach to tackle severe acne effectively.Founded in 2014 and headquartered in Ambler, US, PhotoSonix Medical, Inc. develops advanced treatments for acne through its flagship product, CLENS™. The company raised USD 1.4 mn in Seed funding from Princeton BioPharma Capital Partners on January 26, 2016, to support its growth strategy.PhotoSonix Medical, Inc. specializes in innovative acne treatment solutions, focusing on their flagship investigational device, CLENS™. This advanced therapeutic technology aims to address the pressing issue of moderate to severe acne, which affects over 20 million individuals in the United States alone. CLENS™ operates on a non-drug therapy model, targeting the underlying causes of acne without contributing to the growing problem of antibiotic resistance, as more than 50% of acne bacteria have shown resistance to existing oral antibiotics. The primary clientele includes healthcare providers and dermatologists who seek effective treatments for their patients struggling with acne, as well as patients who are actively seeking non-pharmaceutical alternatives. The company's products primarily cater to the North American market, although there may be potential for expansion into other geographical regions as they continue to develop their offerings.PhotoSonix Medical, Inc. generates revenue through direct sales of its investigational devices and potential partnerships with healthcare providers and dermatological clinics. The transaction structure is primarily B2B, where healthcare institutions purchase the CLENS™ device to provide treatment for their patients. Pricing plans may vary based on institutional contracts and agreements, offering a tailored approach to meet the needs of different client segments. The revenue model aims to establish long-term partnerships with clinics and hospitals seeking to enhance their acne treatment options, thereby ensuring a steady demand for the CLENS™ device. This strategic focus on building relationships within the medical community supports the company's growth and reinforces its position in the market.PhotoSonix Medical, Inc. plans to utilize the USD 1.4 mn raised in Seed funding to enhance its product development efforts, focusing on the design and launch of new acne treatment devices. The company aims to expand its market presence beyond North America, targeting Europe and Asia by 2025. Their strategy includes developing partnerships with dermatological clinics in these regions to introduce CLENS™ and other future products.

## Funding rounds

- Seed, Jan 26, 2016, $1.4M — Princeton BioPharma Capital Partners
- Seed, Aug 20, 2014, $0.1M — Ben Franklin Technology Partners

## Investors

- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Seed
- Princeton BioPharma Capital Partners (https://capitalatlas.ai/funds/princeton-biopharma-capital-partners) — Seed